Objective To characterize the serum kinetics of prostate specific antigen {PSA) after visual laser ablation of the prostate (VLAP). Patients and methods The PSA ve of 45 patients were measured at 24 h and at 1, 4, 12, 26 and 52 weeks after VLAP and the changes assessed in relation to symptom scores, urinary flow rates and prostate size. Results After an initial rise immmediately after VLAP, the serum PSA level declined. At 24 h, the PSA value reached a mean level 23 times higher than the PSA level before VLAP and then took a mean of 78 days to reach a new baseline. The mean decrease of the subsequent baseline value relative to that before treat ment was 1.7 ng/mL. The prostatic size and energy applied correlated positively with the rise in PSA 24 h after VLAP. The rise in maximal urinary llow after VLAP, the decrease in the symptom score and residual urine volume did not correlate with the rise in PSA level 24 h after VLAP or with the time to reach a value halfway between the level at 24 h and the new baseline value. Conclusions The pattern of the increase in serum PSA level and decline after VLAP was not predictive of the clinical outcome of therapy. Keywords Prostate specific antigen, benign prostatic enlargement, laser treatment Introduction PSA is secreted by prostatic epithelial cells into the lumina of the prostate ducts; the concentration of PSA in prostatic secretions is about 106 of that in serum [1] . as it is after TURP [7] , :ic cancer are present. After VLAP, prostatic cancer can develop in the remaining prostatic tissue. Because the heterogenicity of the TRUS image increases after VLAP, the predictive value of TRUS is decreased, Normal prostatic epithelial cells are separated from the capillary and lymphatic system by an intact basal cell layer and basement membrane [2] , When the basal membrane of the prostatic epithelium is disrupted, PSA in the lumen can leak into the serum and increase the serum PSA concentration, invasive treatments like TURP cause a rapid rise in the level of serum PSA [3] [4] [5] [6] ; acini rich in PSA are transected during the operation for BPE and the enzymes are released into the fossa where they are absorbed by the irrigating fluid. After an invasive treatment for BPE, the PSA level increases and the value cannot be used to differentiate reliably between BPE and prostatic cancer until the PSA level attains a new prostate During this post-operative cancer can be detected largely by determining PSA level and by a DRE. The interpretation of serum PSA levels after VLAP is only possible if the kinetics of serum PSA are known. Moreover, an aware ness of the incidence of false-positive findings from PSA after VLAP could reduce unnecessary anxiety in patient, and the need for prostate biopsies.
Introduction
PSA is secreted by prostatic epithelial cells into the lumina of the prostate ducts; the concentration of PSA in prostatic secretions is about 106 of that in serum [1] .
as it is after TURP [7] , :ic cancer are present. After VLAP, prostatic cancer can develop in the remaining prostatic tissue. Because the heterogenicity of the TRUS image increases after VLAP, the predictive value of TRUS is decreased, Normal prostatic epithelial cells are separated from the capillary and lymphatic system by an intact basal cell layer and basement membrane [2] , When the basal membrane of the prostatic epithelium is disrupted, PSA in the lumen can leak into the serum and increase the serum PSA concentration, invasive treatments like TURP cause a rapid rise in the level of serum PSA [3] [4] [5] [6] ; acini rich in PSA are transected during the operation for BPE and the enzymes are released into the fossa where they are absorbed by the irrigating fluid. After an invasive treatment for BPE, the PSA level increases and the value cannot be used to differentiate reliably between BPE and prostatic cancer until the PSA level attains a new prostate During this post-operative cancer can be detected largely by determining PSA level and by a DRE. The interpretation of serum PSA levels after VLAP is only possible if the kinetics of serum PSA are known. Moreover, an aware ness of the incidence of false-positive findings from PSA after VLAP could reduce unnecessary anxiety in patient, and the need for prostate biopsies.
The serum kinetics of PSA after VLAP for BPE have not been characterized sufficiently and the potential prognostic significance for the clinical outcome of vari ables describing the changes in PSA after VLAP are unclear. To address we evaluated the baseline value. In a patient who is considered a candidate changes in the serum PSA levels of patients with UPSS), urollowmetry, a l)RK and (he appearance of the prostate on TRUS. If I heir I'SA level was > 4 ng/mL before treatment , biopsies were taken to exclude prostate After an initial rise caused by VLAP, the serum PSA cancer. All patients underwent elective VLAP side-firing libre; use of and outcome with these level declined (Table 1) ; the times at which PSA was varied slightly from the intended times. The devices has been reported previously |S |. The mean (so) similarity in the values at 12 and 26 weeks suggests prostate volume before treatment was SO (15) mL and that the value attained a new baseline and was no mean ( . The PSA measurements after VLAP were C is the asymptotic value of the baseline reached after VLAP, A determines the value at £ = 1 and B is the rate of the decrease in PSA 24 h after VLAP. The rate of decrease is greater in the first few days after VLAP than in the succeeding weeks and thus the 'half-life' is not optimal parameters quickly. To describe constant but increases steadily. The parameters A, B and the PSA change in each patient, the following variables C were fitted for each of the 45 patients using a weighting were determined: (i) the absolute rise of PSA 24 h after inversely proportional to the square of the PSA values used to obtain the best lit with a mathematical model th a t described accurately the decrease in serum PSA. For each patient, values were fitted using the Marquurdt non-linear regression method, chosen because it usually ?d with the pre-operative value (ÀPSA); (ii) the relative rise of PSA 24 h after surgery compared ?
me weighting for values of 0.5 ng/mL as for . Figure 1 shows the mean PSA value after w i pre-operative value (APSAr); (iii) the time for VLAP in all 45 patients with an example of a double-PSA level to reach a value hallway between the exponential curve fitted to the values. The fitted estimates va at 24 h after VLAP and the •rence new (asymptotic) *en the prebaseline ('172); (iv) operative PSA value and the value at the new baseline and; (v) the time for the PSA level to reach a new baseline (T10%). value 10"' m of of the parameters were used to calculate different charac teristics of the fitted curve.
The mean (sn) PSA level 24 h after VLAP was 103 (59) ng/mL, was 23 (si) 15) times greater than before VLAP. The mean (sd) value of T/2 Correlations between these variables and various other was 5.6 (2.3) days and the mean (sd ) value of T10% was clinical indices were determined using Pearson's method rization). The presence of a 78 (49) days; the mean (s d ) level of the new baseline was 1.7 (2.7) ng/mL below the level before VLAP. Table 2 shows the relationship between the character istics of the PSA curves and the clinical features of the presence of post-operative urinary infection was anapatients. In patients with a large prostate, the rise in Ivsed (or Spearman's, for the duration of ei relationship of these variables with laser-induced cav as seen on TRUS and Student's (-tests for two samples. PSA level was generally greater and the new baseline APSA, PSA at 24 h after VLAP minus the initial value. APSAr, PSA level 24 h after VLAP relative to the initial value. T/2, the time to reach a PSA level halfway between the value at 24 h and at the new baseline. APSAb, the initial PSA level minus that at the new baseline. T10%, the time for the PSA level to reach a value within 10% of the new baseline. Unergy, the amount of energy delivered to the prostate during VLAP. A Volume, the reduction in prostate volume at 26 weeks after VI,AP. SPC, duration of suprapubic catheterization. Cavity, the presence of a cavity on TRUS. Infection, post-operative urinary infection. ns-=not significant (/*>0.05) 7 4 2 7 4 6 the model and the values in Table 1 . The 2 3-fold increase 24 h after VLAP indicates that the tissue was extensively damaged. This rise is comparable with the 14-fold (sd 4) increase of PSA 24 h after transurethral ultrasoundguided laser-induced prostatectomy (TULIP) found by Bosch et al. [9] . However, it is much higher than the 5.9ng/m L increase 18-24 h after TURP reported by Oesterling et al. [3] . Using the Yang assay, Stamey et a l remains in the prostate for a long time after treatment 4] reported a 53-fold rise in PSA concentration in six with high-intensity focused ultrasound, transurethral patients immediately alter I IJRP lor BPE; Vesey et a l [5] needle ablation and transurethral microwave thermoeported that PSA levels rose ninefold immediately after therapy, the time necessary for serum PSA levels to
--prostatectomy than after TURP. A possible explanation could be the altered architecture of the prostate after VLAP, with necrotic tissue remaining in situ rather than being immediately resected as in TURP. The lower level of PSA at the new baseline after VLAP compared with the level before treatment may reflect the ablation of PSA-producing tissue during VLAP. As necrotic tissue r T Price et a l [6 3ls at 1, 3, 5 reach a new baseline after these procedures should be ind 4-2 days after TURP; PSA levels were elevated on comparable with that after VLAP. days 1, 3 and 5 among patients with BPE and gradually
In the present study, the T10% of a high proportion of decreased to below the baseline value by 42 days.
the patients was reached within 4 months; if the PSA rise of PSA alter TURP with the rise after level does not decline to a new baseline 4 months after laser ablation ol the prostate, Kabalin et al, [10] reported VLAP, further management of the patient will depend similar peak levels alter both procedures; however, the on the decisions of the individual clinician and such peak value occurred immediately after TURP, in the patients may represent a high-risk group for prostate ecovery room, but 24 h alter laser ablation. The differcancer. Because serum PSA values vary within an r enee TURP and VLAP in the time taken to individual, measurements must be repeated to confirm reach the peak PSA level, and the different impact on any suspicious increase. We recommend that biopsies prostatic tissue, might explain the different responses in are taken when the PSA is consistently and significantly PSA level post-operatively reported by these authors. above the pre-operative level during this period. An According to Stamey et al. [12] and Vesey et al. [5] , a alternative approach is to keep these patients under dramatic rise in serum PSA immediately after TURP prospective review, using DRE, PSA measurements and implies BPE rather than prostate cancer, as they found TRUS at 6-monthly intervals. If a new baseline PSA insignificant or much smaller increases in serum PSA in value is reached and the serum PSA starts to rise again the latter after TURP. Vesey et a l [5] suggested that this after VLAP, the percentage PSA increase with time (PSA difference could be caused by a more easily extractable slope) may be used to distinguish patients with carcistore of PSA in the dilated acinar spaces of hyperplastic noma. Oesterling et al. [13] found that a rise of >20% tissue, containing pooled prostatic secretions rich in PSA.
per year indicated carcinoma. Accordingly, Feneley et al. In the present study, the decrease in the PSA level [7] reported that serial measurements of PSA in patients after VLAP followed a double-exponential curve. In this with incidental carcinoma found after TURP allowed the model, the 'half-lile' is not constant but increases steadily, disease activity to be monitored and a PSA slope 20% which could be explained by an initial sharp decline in per year was the most accurate marker to predict biopsy-PSA level caused by the disappearance of the sequestered proven residual disease. Although no malignancy was PSA that leaked into the blood during VLAP, after which found in the present patients with increasing PSA levels there was less but persistent leakage of PSA from damone year after VLAP, the PSA slope might be helpful in aged prostatic tissue. The half-life of serum PSA has diagnosing prostate carcinoma after VLAP. been calculated by Oesterling et a l 111] to be 3.15 days,
In conclusion, because of the effects of VLAP on serum using the Tandem-R PSA assay, and by Stamey et al.
PSA it is not useful to measure PSA for the 4 months 12] to be 2.2 days, using the Pros-Check PSA assay.
after VLAP. The kinetics of serum PSA level after VLAP The 'half-life' of 5.6 days 24 h after VLAP is considerably provided no useful information to predict the clinical longer and supports the hypothesis that the decrease in outcome. PSA after VLAP is by damaged prostatic The attainment of a new (lower) mean (sd) baseline at 78 (49) days after VLAP is comparable with References that found by Bosch et al. [9] after TULIP. However, it is considerably longer than the median time required for the serum PSA value to return to a stable level after TURP, as found by 13] (18 days, range 12-30 + ). This also agrees with Kabalin et al. [10] who found that PSA levels decreased more slowly after laser 1 
PSA is secreted by prostatic epithelial cells into the lumina of the prostate ducts; the concentration of PSA in prostatic secretions is about 106 of that in serum [1] . as it is after TURP [7] , :ic cancer are present. After VLAP, prostatic cancer can develop in the remaining prostatic tissue. Because the heterogenicity of the TRUS image increases after VLAP, the predictive value of TRUS is decreased, Normal prostatic epithelial cells are separated from the capillary and lymphatic system by an intact basal cell layer and basement membrane [2] , When the basal membrane of the prostatic epithelium is disrupted, PSA in the lumen can leak into the serum and increase the serum PSA concentration, invasive treatments like TURP cause a rapid rise in the level of serum PSA [3] [4] [5] [6] ; acini rich in PSA are transected during the operation for BPE and the enzymes are released into the fossa where they are absorbed by the irrigating fluid. After an invasive treatment for BPE, the PSA level increases and the value cannot be used to differentiate reliably between BPE and prostatic cancer until the PSA level attains a new prostate During this post-operative cancer can be detected largely by determining PSA level and by a DRE. The interpretation of serum PSA levels after VLAP is only possible if the kinetics of serum PSA are known. Moreover, an aware ness of the incidence of false-positive findings from PSA after VLAP could reduce unnecessary anxiety in patient, and the need for prostate biopsies.
The serum kinetics of PSA after VLAP for BPE have not been characterized sufficiently and the potential prognostic significance for the clinical outcome of vari ables describing the changes in PSA after VLAP are unclear. To address we evaluated the baseline value. In a patient who is considered a candidate changes in the serum PSA levels of patients with j J for visual laser ablation of the prostate (VLAP), the presence of prostatic carcinoma should be excluded, as during VLAP no tissue is obtained for histopathological examination and consequently it is uncertain whether after they had been treated with VLAP.
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Patients and methods . The PSA measurements after VLAP were C is the asymptotic value of the baseline reached after VLAP, A determines the value at £ = 1 and B is the rate of the decrease in PSA 24 h after VLAP. The rate of decrease is greater in the first few days after VLAP than in the succeeding weeks and thus the 'half-life' is not optimal parameters quickly. To describe constant but increases steadily. The parameters A, B and the PSA change in each patient, the following variables C were fitted for each of the 45 patients using a weighting were determined: (i) the absolute rise of PSA 24 h after inversely proportional to the square of the PSA values used to obtain the best lit with a mathematical model th a t described accurately the decrease in serum PSA. The mean (sn) PSA level 24 h after VLAP was 103 (59) ng/mL, was 23 (sd 15) times greater than before VLAP. The mean (sd) value of T/2 Correlations between these variables and various other was 5.6 (2.3) days and the mean (sd) value of T10% was clinical indices were determined using Pearson's method rization). The presence of a 78 (49) days; the mean (s d ) level of the new baseline was 1.7 (2.7) ng/mL below the level before VLAP. Table 2 shows the relationship between the character istics of the PSA curves and the clinical features of the presence of post-operative urinary infection was anapatients. In patients with a large prostate, the rise in Ivsed (or Spearman's, for the duration of ei relationship of these variables with laser-induced eav as seen on TRUS and Student's (-tests for two samples. PSA level was generally greater and the new baseline was ret sooner. The energy given during VLAP correlated moderately with the rise in PSA 24 h after VLAP but there was no significant correlation between the characteristics of the PSA curves i 3 rise m VLAP (P -0.01). The duration of suprapubic catheteriz ation was negatively correlated with the relative rise of PSA at 24 h after VLAP, T/2, the new baseline and with TK)%. In patients where there was a laser-induced cavity, as detected using TRUS 26 weeks after VLAP, there was a significantly higher mean value lor PSAr at 24 h, T/ and TU)%. In patients with a urinary infection postoperatively, the mean T/2 was significantly lower. At 26 weeks after VLAP, the serum PSA level was > 10.0 and than re VLAP in two patients; these patients underwent TRUS-guided prostatic biopsies, taking three cores from the right and the left apex. The slant from base and histopathologieal examination revealed focal invasion of white blood cells a normal pattern of prostatic acini.
Discussion
The fitted parameters from the curve for each patient were used for am I n * than the maximum urinary flow rate after VLAP, the decrease in the IPSS or the decrease in residual urine volume. There was a weak correlation (r = 0.45) between the decline in serum PSA level at the new baseline compared with values, thus partly correcting for any variation in the the PSA value before VLAP and with the reduction in actual sampling time, and explaining the differences in prostate volume as measured with TRUS 26 weeks after the increase in PSA level at 24 h after VLAP between Bosch et al. [9] . However, it is much higher than the 5.9ng/m L increase 18-24 h after TURP reported by
Oesterling et al. [3] . [6 3ls at 1, 3, 5 reach a new baseline after these procedures should be ind 4-2 days after TURP; PSA levels were elevated on comparable with that after VLAP. days 1, 3 and 5 among patients with BPE and gradually
the patients was reached within 4 months; if the PSA rise of PSA alter TURP with the rise after level does not decline to a new baseline 4 months after laser ablation ol the prostate, Kabalin et al. [10] reported VLAP, further management of the patient will depend similar peak levels after both procedures; however, the on the decisions of the individual clinician and such peak value occurred immediately after TURP, in the patients may represent a high-risk group for prostate ecovery room, but 24 h alter laser ablation. The differcancer. Because serum PSA values vary within an r enee TURP and VLAP in the time taken to individual, measurements must be repeated to confirm reach the peak PSA level, and the different impact on any suspicious increase. We recommend that biopsies prostatic tissue, might explain the different responses in are taken when the PSA is consistently and significantly PSA level post-operatively reported by these authors. above the pre-operative level during this period. An
According to Stamey et al. [12] and Vesey et al [5] , a alternative approach is to keep these patients under dramatic rise in serum PSA immediately after TURP prospective review, using DRE, PSA measurements and implies BPE rather than prostate cancer, as they found TRUS at 6-monthly intervals. If a new baseline PSA insignificant or much smaller increases in serum PSA in value is reached and the serum PSA starts to rise again the latter after TURP. Vesey et al [5] suggested that this after VLAP, the percentage PSA increase with time (PSA difference could be caused by a more easily extractable slope) may be used to distinguish patients with carcistore of PSA in the dilated acinar spaces of hyperplastic noma. Oesterling et al. [13] found that a rise of >20% tissue, containing pooled prostatic secretions rich in PSA.
per year indicated carcinoma. Accordingly, Feneley et al.
In the present study, the decrease in the PSA level [7] reported that serial measurements of PSA in patients after VLAP followed a double-exponential curve. In this with incidental carcinoma found after TURP allowed the model, the 'half-life' is not constant but increases steadily, disease activity to be monitored and a PSA slope 20% which could be explained by an initial sharp decline in per year was the most accurate marker to predict biopsy-PSA level caused by the disappearance of the sequestered proven residual disease. Although no malignancy was PSA that leaked into the blood during VLAP, after which found in the present patients with increasing PSA levels there was less but persistent leakage of PSA from damone year after VLAP, the PSA slope might be helpful in aged prostatic tissue. The half-life of serum PSA has diagnosing prostate carcinoma after VLAP.
been calculated by Oesterling et al. I 'll] to be 3.15 days,
after VLAP. The kinetics of serum PSA level after VLAP The'half-life' of 5.6 days 24 h after VLAP is considerably provided no useful information to predict the clinical longer and supports the hypothesis that the decrease in outcome. PSA after VLAP is by damaged prostatic The attainment of a new (lower) mean (sd) baseline at 78 (49) days after VLAP is comparable with References that found by Bosch et al. [9] after TULIP. However, it is considerably longer than the median time required for the serum PSA value to return to a stable level after TURP, as found by 13] (18 days, range 12-30 + ). This also agrees with Kabalin et al. [10] who found that PSA levels decreased more slowly after laser
